RC
Rangeley Capital Portfolio holdings
AUM
$79.7M
This Quarter Return
+19.63%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$79.7M
AUM Growth
-$8.91M
(-10%)
Cap. Flow
-$13.8M
Cap. Flow
% of AUM
-17.33%
Top 10 Holdings %
Top 10 Hldgs %
56.15%
Holding
112
New
39
Increased
13
Reduced
18
Closed
40
Top Buys
| 1 |
Prothena Corp
PRTA
|
$4.34M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$3.15M |
| 3 |
ITOS
iTeos Therapeutics
ITOS
|
$3.01M |
| 4 |
Core Scientific, Inc. Tranche 1 Warrants
CORZW
|
$2.5M |
| 5 |
Skechers
SKX
|
$2.27M |
Top Sells
| 1 |
Burford Capital
BUR
|
$4.28M |
| 2 |
Calumet Specialty Products
CLMT
|
$3.16M |
| 3 |
Amplify Energy
AMPY
|
$2.69M |
| 4 |
Liquidia Corp
LQDA
|
$2.36M |
| 5 |
Par Pacific Holdings
PARR
|
$2.02M |
Sector Composition
| 1 | Healthcare | 49.36% |
| 2 | Energy | 13.18% |
| 3 | Real Estate | 8.81% |
| 4 | Consumer Discretionary | 8.17% |
| 5 | Materials | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
THTX
51
Theratechnologies
THTX
$150M
| $118K | 0.14% |
+50,000
| New | +$118K |
|
|
TMQ
52
Trilogy Metals
TMQ
$327M
| $117K | 0.14% |
87,000
-11,074
| -11% | -$15K |
|
53
Mural Oncology
MURA
$35.9M
| $115K | 0.14% |
+46,513
| New | +$115K |
|
|
SBXD
54
SilverBox Corp IV
SBXD
$267M
| $110K | 0.13% |
+10,000
| New | +$110K |
|
|
OKUR
55
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$35.6M
| $71.5K | 0.09% |
+29,902
| New | +$71.5K |
|
56
Pliant Therapeutics
PLRX
$106M
| $69.9K | 0.08% |
60,220
+10,220
| +20% | +$11.9K |
|
57
AN2 Therapeutics
ANTX
$32.5M
| $68.9K | 0.08% |
65,000
+15,000
| +30% | +$15.9K |
|
58
4D Molecular Therapeutics
FDMT
$326M
| $48.2K | 0.06% |
+13,000
| New | +$48.2K |
|
|
AKYA
59
DELISTED
Akoya BioSciences
AKYA
| $42.9K | 0.05% |
+33,035
| New | +$42.9K |
|
60
Vivid Seats
SEAT
$105M
| $42.3K | 0.05% |
+1,250
| New | +$42.3K |
|
61
PepGen
PEPG
$48.9M
| $38.9K | 0.05% |
35,000
+20,000
| +133% | +$22.2K |
|
62
LAVA Therapeutics
LVTX
$40.8M
| $35.7K | 0.04% |
+27,073
| New | +$35.7K |
|
63
MacroGenics
MGNX
$111M
| $32.7K | 0.04% |
+27,000
| New | +$32.7K |
|
64
Nuvation Bio
NUVB
$1.19B
| $25.4K | 0.03% |
+13,000
| New | +$25.4K |
|
65
MEI Pharma
MEIP
$98.5M
| $24.7K | 0.03% |
+10,000
| New | +$24.7K |
|
66
Cabaletta Bio
CABA
$154M
| $24.3K | 0.03% |
+16,000
| New | +$24.3K |
|
67
Zura Bio
ZURA
$144M
| $22.1K | 0.03% |
+21,000
| New | +$22.1K |
|
68
Seer Inc
SEER
$114M
| $21.4K | 0.03% |
+10,000
| New | +$21.4K |
|
69
NovaBay Pharmaceuticals
NBY
$15.7M
| $19.3K | 0.02% |
+33,210
| New | +$19.3K |
|
70
Synlogic
SYBX
$17.2M
| $17.3K | 0.02% |
+13,597
| New | +$17.3K |
|
71
Atlanta Braves Holdings Series B
BATRK
$2.66B
| – | – |
-5,981
| Closed | -$239K |
|
72
BridgeBio Pharma
BBIO
$10.4B
| – | – |
-13,000
| Closed | -$449K |
|
73
BankFinancial
BFIN
$154M
| – | – |
-89,000
| Closed | -$1.12M |
|
74
Bausch + Lomb
BLCO
$5.49B
| – | – |
-15,000
| Closed | -$218K |
|
75
Cardlytics
CDLX
$48.5M
| – | – |
-130,000
| Closed | -$237K |
|